GEN-MKT-18-7897-A
Sep 13, 2018 | Blogs, Software, Technology | 0 comments
Advances in today’s technology have resulted in a need for higher and faster sample throughput, with increasing number of measured analytes per sample. The new SCIEX OS-MQ software breaks the routine and takes quantitation workflows to a new level.
Key features include:
Featuring a sleek, intuitive user interface combined with the peak integration algorithm, which allows you to automatically remove outliers from a calibration curve, and includes new tools for flagging and filtering results. Built from the software you already know and trust, these new features and more make data processing and review more streamlined and efficient than ever before, quick to learn and simple to master. The new SCIEX OS 1.4 was designed to support 21 CFR Part 11 Compliance, providing tools such as the incorporation of electronic audit trails, electronic signatures, and detailed security configurations. For those upgrading to SCIEX OS-MQ, a major benefit is the Explorer workspace, which provides the functionality for manual investigation of data similar to PeakView Software. With next-generation SCIEX OS-MQ software, you can be confident that you will achieve accurate and reliable results that address your laboratory requirements and increase overall laboratory productivity.
Read the latest tech note on how SCIEX is Improving Routine Quantitation Workflows in SCIEX OS-MQ.For more questions on upgrading, get in touch with a software specialist today >
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
CE‑SDS remains a cornerstone assay for characterizing fragmentation, aggregation, and product‑related impurities in therapeutic proteins. UV detection has been the long‑standing standard. However, it frequently struggles with baseline noise, limited sensitivity for minor fragments, and subjective integration.
At SCIEX, innovation doesn’t stop at instruments; it extends to how you interact with your LC-MS/MS or CE systems every day. That’s why we’re excited to introduce the SCIEX Now spring 2026 improvements: a set of meaningful enhancements shaped directly by your feedback.
Posted by
You must be logged in to post a comment.
Share this post with your network